Fact CheckerSign in

NCT06657274Recruiting

EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069

Source: ClinicalTrials.gov · Last updated 2 May 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The increase in life expectancy in recent decades has led to a large number of people living into old age and an increased risk of developing Chronic Neurological Diseases (CNDs) such as neurodegenerative diseases. A higher cumulative risk of dementia has been largely demonstrated in Mild Cognitive Impairment (MCI) and Subjective Cognitive Complaints (SCCs) subjects and in Parkinson's Disease (PD) patients, as compared to the general population. These disorders result in an impairment of the individual's abilities to perform daily tasks. As their disease progresses, patients become dependent on medical services and on family support. Given the limited effectiveness of pharmacological treatments, non-pharmacological interventions to prevent and treat cognitive deficits and the associated difficulties with activities of daily living in neurodegenerative disease patients have gained attention in recent years and, among these, cognitive training offers a potential approach for dementia prevention and improvement of cognitive function. A critical aspect of cognitive training programs is that the most promising interventions have involved intensive in-person sessions that are unlikely to be cost-effective or feasible for large-scale implementation. Within the framework of non-pharmacological interventions, the use of technology to assist the person at risk and/or with mild dementia at home and to extend rehabilitation services in the treatment of dementia has gradually gained importance. Telerehabilitation technologies allow to provide services remotely in patients' homes, allowing access to health care to patients living in rural settings or with mobility difficulties. In addition, the telerehabilitation modality offers the advantage of providing rehabilitation within the natural environment of the patient's home, making the treatment more realistic and possibly more generalizable to the person's daily life. The present project proposes to test a home-based asynchronous cognitive telerehabilitation program aimed at enhancing the continuum of care for MCI, SCCs and PD, using technology. The proposed study is a single blind randomized controlled trial (RCT) involving subjects with CNDs randomly assigned to one out of two intervention groups: i) the tele@cognitive group, who will receive at-home cognitive telerehabilitation (tele@cognitive treatment); ii) the Active Control Group (ACG), who will receive at-home unstructured cognitive stimulation. The aim of the project will be threefold: \[1\] to test the short-term and long-term efficacy of tele@cognitive protocol as compared to an unstructured cognitive at-home rehabilitation in the treatment of a cohort of patients with CNDs; \[2\] to explore the changes induced by tele@cognitive intervention on biomolecular and neurophysiological markers; \[3\] to explore potential cognitive, neurobiological and neurophysiological predictors of response to tele@cognitive treatment.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
60 (estimated)
First submitted
23 Oct 2024
Start date
9 Dec 2024
Primary completion date
30 Aug 2026
Lead sponsor
IRCCS Centro San Giovanni di Dio Fatebenefratelli
NCT number
NCT06657274

What you commit to

  • Study type: Interventional
  • Planned participants: 60
  • From 9 Dec 2024 to the primary completion date, 30 Aug 2026
  • 3 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Presence of any medical or psychiatric illness that could interfere with completing assessments;
  • Presence of any medical condition representing a contraindication to TMS.

Who the study is looking for

  • Diagnosis of PD (Hoehn \& Yahr\<3); MCI (with CDR scale≤0.5, MMSE ≥24), and SCC (Subjective Cognitive Complaints);
  • Montreal Cognitive Assessment (MoCA) corrected score ≥17.36
  • Education ≥ 5 years
  • Age eligible for the study: 18≤age≤85
  • Native Italian speakers
  • Absence of marked hearing/visual impairment
  • All of the subjects will have normal or corrected-to-normal vision.
  • Agreement to participate by signing the informed consent form
  • Availability of a caregiver/study partner able to support the participant
  • No rehabilitation program in place at the time of enrolment or in the last 3 months before enrolment
  • Stable drug treatment (last 3 months), if any

Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli
Coordinator of this site? Confirm its status
BresciaItalyRecruiting
IRCCS Centro Neurolesi Bonino Pulejo
Coordinator of this site? Confirm its status
MessinaItalyRecruiting
Fondazione Don Carlo Gnocchi - ONLUS, Milan
Coordinator of this site? Confirm its status
MilanItalyRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.